The combination of polymorphisms within interferon-γ receptor 1 and receptor 2 associated with the risk of systemic lupus erythematosus  by Nakashima, Hitoshi et al.
The combination of polymorphisms within interferon-Q receptor 1 and
receptor 2 associated with the risk of systemic lupus erythematosus
Hitoshi Nakashima*, Hisako Inoue, Mitsuteru Akahoshi, Yosuke Tanaka,
Kunihiro Yamaoka, Eiichi Ogami, Shuuji Nagano, Yojiro Arinobu, Hiroaki Niiro,
Takeshi Otsuka, Yoshiyuki Niho
First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka 812-8582, Japan
Received 14 April 1999; received in revised form 11 May 1999
Abstract Genetic factors seem to play a significant role in
susceptibility to systemic lupus erythematosus (SLE). We
previously described the amino acid polymorphism (Val14Met)
within the IFN-Q receptor 1 (IFN-QR1), and that the frequency of
the Met14 allele in SLE patients was significantly higher than
that of the healthy control population [Tanaka et al. (1999)
Immunogenetics 49, 266^271]. We also found an amino acid
polymorphism (Gln64Arg) within IFN-Q receptor 2 (IFN-QR2).
Since the IFN-Q receptor is a complex consisting of IFN-QR1 and
IFN-QR2, we searched for the particular combination of two
kinds of amino acid polymorphisms found within the IFN-Q
receptor which plays a prominent role in susceptibility to SLE.
The greatest risk of the development of SLE was detected in the
individuals who had the combination of IFNGR1 Met14/Val14
genotype and IFNGR2 Gln64/Gln64 genotype.
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1. Introduction
Systemic lupus erythematosus (SLE) is characterized by
multisystem in£ammation and the production of autoantibod-
ies by activated B lymphocytes and by decreased cellular im-
mune responses related to a dysregulation of T lymphocytes.
Autoantibodies can generate immune complexes and may
cause tissue damage through the recognition of an autoanti-
gen. Although many factors have been proposed, such as
genetic factors, environmental factors, hormonal action, vi-
ruses and dysregulation of cytokine production, the cause of
this disease is not well understood.
Interferon-Q (IFN-Q) is a secretory protein produced by ac-
tivated T lymphocytes and natural killer (NK) cells. On bind-
ing to a speci¢c cell surface receptor complex consisting of
IFN-Q receptor ligand-binding chain (IFN-QR1) and IFN-Q
receptor signal-transducing chain (IFN-QR2) [2,3], IFN-Q in-
duces antiviral activity, upregulation of class II major histo-
compatibility complex (MHC) molecule expression, B cell ma-
turation, and release of mediators of in£ammation [4^6]. The
predominance of either Th1 or Th2 immune response can
have great signi¢cance for many disease conditions, and
IFN-Q as well as interleukin-2 is mainly responsible for the
Th1 response, cell-mediated immunity [7].
We have reported that the frequency of the amino acid
polymorphism (Val14Met) in IFN-QR1 in SLE patients was
signi¢cantly higher than in the healthy control population,
which suggested that this polymorphism in£uenced the sus-
ceptibility to SLE as one of the genetic factors[1]. We found
an amino acid polymorphism (Gln64Arg) in IFN-QR2, and
clari¢ed that the particular combination of these two kinds
of amino acid polymorphism is associated with the suscepti-
bility to SLE.
2. Materials and methods
2.1. Patients and healthy controls
This study included 96 outclinic patients with SLE (13 males and
83 females, mean age 40.9, S.D. 12.65, range 16^78 years old), and
91 healthy control volunteers (10 males and 81 females, mean age
40.1, S.D. 13.01, range 17^76 years old). All the patients met more
than four of the American Rheumatism Association revised criteria
for the diagnosis of SLE.
2.2. RT-PCR SSCP analysis of the IFNGR2 cDNA sequence
Total RNA was extracted from peripheral mononuclear cells
(2U107 cells) of 200 unrelated Japanese individuals by the guanidi-
nium isothiocyanate/phenol extraction method (Isogen, Nippon Gene
Ltd., Tokyo, Japan). One-tenth of the total RNA preparation was
used in ¢rst-strand cDNA synthesis (RNA PCR Kit; PE Biosystems
Japan Ltd., Urayasu, Japan). One-¢fth of the cDNA reaction mixture
was used as a template in polymerase chain reaction (PCR), and
cycling conditions for PCR were an initial 2 min at 94‡C, followed
by 1 min at 94‡C, and 1 min at 60‡C for 35 cycles, with an extension
time of 7 min at 72‡C. Three pairs of synthetic oligonucleotides, which
were about 400 bp apart, were selected to amplify three segments,
which were named YF-AFI, YF-AFII and YF-AFIII (Table 1). The
whole segments almost covered the IFNGR2 open reading frame
(1012 nucleotides) starting from nucleotide position 649 and ending
at position 1660, which is a part of the published cDNA clone se-
quence [2]. A mixture of 2 Wl of PCR products and the same amount
of denaturing solution (95% formamide, 0.1% BPB, 0.1% xylene cya-
nol) was heated for 5 min at 94‡C and chilled on ice before being
applied to a 10% polyacrylamide gel plate (acrylamide:bis = 49:1,
0.8 mmU8.0 cmU9.0 cm). Electrophoresis was performed at a con-
stant voltage of 45 V for 12 h. After electrophoresis, the DNA bands
were visualized by the silver staining method [8] with a commercially
available reagent kit (Daiichi Pure Chemicals, Tokyo, Japan). DNAs
showing variations on electrophoresis were cloned into the pT7blue T
vector (Novagen Ltd., Madison, WI, USA) and then sequenced. Silver
staining of PCR products yielded consistent results.
2.3. Detection of polymorphism within the IFNGR2 cDNA sequence
We detected a polymorphism within the IFNGR2 cDNA sequence
as described in Section 3. Since the polymorphism did not create or
destroy any restriction enzyme sites, detection by mismatch-PCR/
RFLP was performed [9,10]. The sequence of the forward primer
(named HNQ64R-U678) is 5P-CTG CTG CTG CTC GGA GTC
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TTC-3P. The reverse primer, HNQ64R-L866 (sequence: 5P-ACT GTC
GGT GTA TTT AAA CTG AGC T-3P), contains a 2 bp mismatch
(underlined) just proximal to its 3P end such that the 189 bp ampli¢ed
product incorporates a restriction site for the endonuclease SacI in the
presence of guanine at nucleotide 839, but not in the presence of
adenine (Fig. 1). DNAs digested with 5 units of SacI under the con-
ditions recommended by the manufacturer (New England Biolab,
Inc., Beverly, MA, USA) were size-separated by 4% agarose gel elec-
trophoresis. SacI digestion of the PCR amplicon produced 170 bp and
19 bp products for the G839 allele, and an intact 189 bp product for
the A839 allele.
2.4. Detection of the polymorphism within the IFNGR1 cDNA sequence
The determination of the genotypes for IFNGR1 cDNA was per-
formed by the method previously described [1]. Brie£y, RT-PCR was
performed with the reverse primer (YT-1: 5P-GTA AAA ACA GGG
ACC TGT GGC ATG-3P) and the forward primer (YT-2: 5P-CTC
CTA CCC CTT GTC ATG CAG GAT-3P). The forward primer YT-2
contains a 1 bp mismatch (underlined) just proximal to its 3P end such
that the 164 bp ampli¢ed product incorporates a restriction site for
the endonuclease FokI in the presence of guanine at nucleotide 88, but
not in the presence of adenine. FokI digestion of the PCR amplicon
produced 130 bp and 34 bp products for the G88 allele (Val14 allele),
and an intact 164 bp product for the A88 allele (Met14 allele). We
were not able to detect any individual homozygous for the Met14
allele (Fig. 2).
2.5. Statistical analysis
Crude odds ratios (OR) and 95% con¢dence intervals (CI) were
calculated from logistic regression models by the PC-SAS version
6.04 (SAS Institute, Inc., Cary, NC, USA). The reported P values
are two-sided and considered signi¢cant at P9 0.05.
3. Results
DNA variants observed in RT-PCR SSCP analysis with
YF-AFI primers were sequenced and the sole single base sub-
stitution of guanine for adenine at nucleotide 839 (A839G)
was identi¢ed. This substitution occurred at the second posi-
tion of codon 64 (CAA to CGA), and led to an amino acid
substitution of arginine for glutamine (Gln64Arg). This poly-
morphism can be detected by the mismatch-PCR/RFLP meth-
od. The endonuclease SacI digestion of the PCR amplicon
discriminated between the Gln64 allele and Arg64 allele, re-
sulting in a 189 bp product, and 170 bp and 19 bp products,
respectively (Fig. 2). We could determine the genotype for
IFNGR2 as well as IFNGR1.
The distribution of IFNGR1 and IFNGR2 genotypes is pre-
sented in Table 2, and we calculated ORs based on single
genotype in SLE cases and healthy controls in Table 3. There
was a signi¢cant association between IFNGR1 genotypes and
SLE. The IFNGR1 Met14 genotype increased the risk of SLE
(OR 4.0, 95% CI 1.3^12.6, P = 0.02). We have already re-
ported that the proportion of the IFNGR1 genotype was stat-
istically signi¢cantly di¡erent between SLE cases and healthy
controls [1]. But there was no signi¢cant association between
IFNGR2 genotypes and SLE.
Fig. 1. Mismatch-RT-PCR primer for detection of polymorphism
within the IFNGR2 cDNA sequence. (1) A part of the IFN-QR2
amino acid sequence. (2) A part of the nucleotide sequence of the
IFNGR2 cDNA open reading frame. The DNA polymorphism is lo-
cated at nucleotide 839 from the starting of cDNA. The polymor-
phism A839G (underlined) leads to an amino acid substitution at
position 64 (Gln64Arg). (3) Reverse primer for mismatch-RT-PCR/
RFLP analysis. This primer, named HNQ64R-L866, contains a 2 bp
mismatch (underlined) just proximal to its 3P end. (4) Endonuclease
SacI recognition site sequence. (5) The 3P terminal sequence of PCR
product in the presence of guanine at nucleotide 839 (underlined)
incorporates a recognition site for the endonuclease SacI, but not in
the presence of adenine.
Table 1
Sequence of oligonucleotides for PCR
Primer Sequence Sequence
region (nt)
Size of the
ampli¢ed
fragment
(bp)
YF-AFI Forward: 5P-
GACCTGAGCCGCCGCCGAGCG-3P
619^639 342
Reverse: 5P-
GCCTGCTGAGGGACTGGCGGC-3P
940^960
YAF-AFII Forward: 5P-
CAGAGTGTGACTTCACTGCCG-3P
923^943 375
Reverse: 5P-
GCAGTTGTGCCTGGACTTGTA-3P
1277^1297
YF-AFIII Forward: 5P-
AAAACCCTCCAGAGTGTACTG-3P
1254^1274 428
Reverse: 5P-
CTAGGCCCATGCTTTGGTTCA-3P
1660^1681
Fig. 2. Genotyping for IFNGR1 and IFNGR2 by mismatch-RT-PCR/RFLP. IFNGR1 genotype: The ampli¢ed products from RNAs using
primers YT-1 and YT-2 were digested with endonuclease FokI and electrophoresed on a 4% agarose gel. Ethidium bromide-stained DNAs
show RFLP. FokI digestion of the PCR amplicon produced 130 bp and 34 bp products for the Val14 allele, and an intact 164 bp product for
the Met14 allele. We were not able to detect any homozygous for the Met14 allele. IFNGR2 genotype: The ampli¢ed products from RNAs
using primers YF-AFII-U678 and HNQ64R-L866 were digested with endonuclease SacI and electrophoresed on a 4% agarose gel. SacI
digestion of the PCR amplicon produced 170 bp and 19 bp products for the Arg64 allele, and an intact 189 bp product for the Gln64 allele.
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In Table 5, we show ORs based on genotype combination
in SLE cases and healthy controls. The greatest risk was de-
tected in individuals having the combination of the IFNGR1
Met14/Val14 genotype and the IFNGR2 Gln64/Gln64 geno-
type (OR 9.6, 95% CI 1.1^85.7, P = 0.04). The other combi-
nations did not have signi¢cantly increased risk.
4. Discussion
We found a genetic polymorphism of A839G within
IFNGR2. This polymorphism led to an amino acid substitu-
tion of arginine for glutamine (Gln64Arg) within IFN-QR2. In
fact, this substitution had already been described in the report
of the IFN-QR2 cloning work [2]. A genetic polymorphism
(Val14Met) within IFN-QR1, which is another component of
the IFN-Q receptor, was also reported [1].
In this work we studied the association between the geno-
type combination of these IFN-QR polymorphisms and SLE.
Our data show that there was no association between IFN-
QR2 genotype and SLE (Table 3). However, the risk of SLE
associated with the IFN-QR1 Met14/Val14 genotype was con-
¢ned to individuals whose IFN-QR2 genotypes were Gln64/
Gln64 (OR = 9.6 in Gln64/Gln64 vs. OR = 3.6 in Arg64/
Arg64). This result suggests the possibility of an interaction
between the two polymorphisms (Table 5). Although the di-
rect tests for interaction between these genotypes showed no
statistically signi¢cant e¡ect, it was probably due to small
sample sizes. The IFN-QR2 Gln64/Gln64 genotype was not
risk factor among the individuals whose IFN-QR1 genotype
was Val14/Val14 (Table 4).
The physiological mechanism behind these associations is
not clear. Although there was no di¡erence in the receptor
function concerning HLA-DR expression induction of B cells
between Gln64 IFN-QR2 and Arg64 IFN-QR2 [2], the function
of B cells bearing variant IFN-QR1 (Met14/Val14) was signi¢-
cantly reduced compared with that of normal receptor B cells
(Val14/Val14) [1]. The combination of IFN-QR1(Met14/Val14)
and IFN-QR2(Gln64/Gln64) may induce synergistic dysfunc-
tion of the receptor. But we consider that these polymor-
phisms do not play a direct role in pathogenesis of SLE,
but are members of genetic factors which may induce the
development of this disease by combination with other loci
or other circumstances. In fact, there was a normal individual
carrying these polymorphisms (Table 4). Further accumula-
tion of knowledge on genetic polymorphisms concerning the
cytokine network would deepen our understanding of the ge-
netic factors involved in SLE.
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Table 3
Odds ratio based on single genotype in SLE cases and healthy con-
trols
Genotype Crude OR (95% CI) P
IFNGR1
Val14/Val14 1.0
Met14/Val14 4.0 (1.3^12.6) 0.02
IFNGR2
Arg64/Arg64 1.0
Arg64/Gln64 1.0 (0.5^2.1) 0.98
Gln64/Gln64 1.5 (0.6^3.5) 0.36
Table 2
Distribution of IFNGR1 and IFNGR2 genotypes in SLE and
healthy controls
Genotype Cases
(n = 96)
Healthy controls
(n = 91)
IFNGR1
Val14/Val14 0.84 (81) 0.96 (87)
Met14/Val14 0.16 (15) 0.04 (4)
IFNGR2
Arg64/Arg64 0.19 (18) 0.21 (19)
Arg64/Gln64 0.49 (47) 0.55 (50)
Gln64/Gln64 0.32 (31) 0.24 (22)
Table 4
Distribution of genotype combinations between IFNGR1 and IFNGR2 in SLE cases and healthy controls
IFNGR1 : Val14/Val14 IFNGR1 : Met14/Val14
Controls (n = 87) Cases (n = 81) Controls (n = 4) Cases (n = 15)
IFNGR2
Arg64/Arg64 0.21 (18) 0.16 (15) 0.25 (1) 0.20 (3)
Arg64/Gln64 0.55 (48) 0.53 (43) 0.5 (2) 0.27 (4)
Gln64/Gln64 0.24 (21) 0.28 (23) 0.25 (1) 0.53 (8)
IFNGR2 : Arg64/Arg64 FNGR2 : Arg64/Gln64 FNGR2 : Gln64/Gln64
Controls (n = 19) Cases (n = 18) Controls (n = 50) Cases (n = 47) Controls (n = 22) Cases (n = 31)
IFNGR1
Val14/Val14 0.95 (18) 0.83 (15) 0.96 (48) 0.91 (43) 0.95 (21) 0.74 (23)
Met14/Val14 0.05 (1) 0.17 (3) 0.04 (2) 0.09 (4) 0.05 (1) 0.26 (8)
Table 5
Odds ratio based on genotype combination in SLE cases and
healthy controls
Genotype combination Crude OR (95% CI) P
IFNGR1 IFNGR2
Val14/Val14 Arg64/Arg64 1.0
Arg64/Gln64 1.1 (0.5^2.4) 0.86
Gln64/Gln64 1.3 (0.5^3.3) 0.55
Met14/Val14 Arg64/Arg64 3.6 (0.3^38.3) 0.29
Arg64/Gln64 2.4 (0.4^15.0) 0.35
Gln64/Gln64 9.6 (1.1^85.7) 0.04
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